Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 4/20 | 0.42 |
| ▸ | SLC1A2 | P43004 | 4/20 | 0.42 |
| ▸ | SLC1A1 | P43005 | 4/20 | 0.42 |
| ▸ | CPN1 | P15169 | 2/20 | 0.39 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.39 |
| ▸ | ANPEP | P15144 | 1/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.37 |
| ▸ | LTA4H | P09960 | 1/20 | 0.37 |
| ▸ | GRN | P28799 | 1/20 | 0.37 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1733993 | 0.95 | SLC1A3 (0.42) | SLC1A3SLC1A2SLC1A1CPN1CPB2 | |
| SCHEMBL1733951 | 0.92 | SLC1A3 (0.44) | SLC1A3SLC1A2SLC1A1LTA4HGRN | |
| SCHEMBL2861766 | 0.90 | ANPEP (0.44) | SLC1A3SLC1A2SLC1A1CPN1CPB2 | |
| SCHEMBL28301078 | 0.89 | CPB2 (0.42) | SLC1A3SLC1A2SLC1A1CPN1CPB2 | |
| SCHEMBL28277857 | 0.86 | SLC1A3 (0.38) | SLC1A3SLC1A2SLC1A1CPN1CPB2 | |
| SCHEMBL2857810 | 0.85 | ANPEP (0.41) | SLC1A3SLC1A2SLC1A1CPN1CPB2 | |
| SCHEMBL16621534 | 0.82 | ALOX5 (0.35) | SLC1A3SLC1A2SLC1A1ANPEPALOX5 | |
| SCHEMBL3346213 | 0.80 | SLC1A3 (0.40) | SLC1A3SLC1A2SLC1A1CPN1CPB2 | |
| SCHEMBL7495280 | 0.80 | SLC1A3 (0.40) | SLC1A3SLC1A2SLC1A1CPN1CPB2 | |
| SCHEMBL2857737 | 0.79 | GRIN2D (0.42) | SLC1A3SLC1A2SLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102007116-B | Pyridazinone glucokinase activators | HOFFMAN-LA ROCHE LTD. (CH) | 2014-10-22 | — | — | CN | disclosed |
| US-8258134-B2 | Pyridazinone glucokinase activators | HOFFMANN-LA ROCHE INC. (US) | 2012-09-04 | — | — | US | disclosed |
| EP-1896452-B1 | N-FORMYL HYDROXYLAMINE COMPOUNDS | NOVARTIS AG (CH) | 2011-11-16 | — | — | EP | disclosed |
| US-8044199-B2 | N-formyl hydroxylamines compounds | VICURON HOLDINGS LLC (US) | 2011-10-25 | — | — | US | disclosed |
| US-8044199-B2 | N-formyl hydroxylamines compounds | VICURON HOLDINGS LLC (US) | 2011-10-25 | — | — | US | disclosed |
| US-8044199-B2 | N-formyl hydroxylamines compounds | VICURON HOLDINGS LLC (US) | 2011-10-25 | — | — | US | disclosed |
| CN-101193882-B | N-Formyl Hydroxylamine Compounds as PDF Inhibitors | NOVARTIS AG | 2011-09-07 | — | — | CN | disclosed |
| CN-102007116-A | Pyridazinone glucokinase activators | HOFFMANN LA ROCHE | 2011-04-06 | — | — | CN | disclosed |
| EP-2268633-A1 | PYRIDAZINONE GLUCOKINASE ACTIVATORS | F. Hoffmann-La Roche AG (CH) | 2011-01-05 | — | — | EP | disclosed |
| US-20100063278-A1 | N-Formyl Hydroxylamines compounds | NOVARTIS AG (CH) | 2010-03-11 | — | — | US | disclosed |
| US-20090062537-A1 | N-Formyl Hydrozyamine Compounds | LEE KWANGHO | 2009-03-05 | — | — | US | disclosed |
| EP-1994027-A2 | N-FORMYL HYDROXYLAMINE COMPOUNDS | Novartis AG (CH) | 2008-11-26 | — | — | EP | disclosed |
| US-20080161558-A1 | 1-[2-Cyclopentylmethyl-3-(formyl-hydroxy-amino)-propionyl]-pyrrolidine-2-carboxylic acid (5-fluoro-1-oxy-pyridin-2-yl)-amide; inhibitors of peptidyl deformylase (PDF), antimicrobials and antibiotics | VICURON HOLDINGS LLC | 2008-07-03 | — | — | US | disclosed |
| US-20080161558-A1 | 1-[2-Cyclopentylmethyl-3-(formyl-hydroxy-amino)-propionyl]-pyrrolidine-2-carboxylic acid (5-fluoro-1-oxy-pyridin-2-yl)-amide; inhibitors of peptidyl deformylase (PDF), antimicrobials and antibiotics | VICURON HOLDINGS LLC | 2008-07-03 | — | — | US | disclosed |
| US-20080161558-A1 | 1-[2-Cyclopentylmethyl-3-(formyl-hydroxy-amino)-propionyl]-pyrrolidine-2-carboxylic acid (5-fluoro-1-oxy-pyridin-2-yl)-amide; inhibitors of peptidyl deformylase (PDF), antimicrobials and antibiotics | VICURON HOLDINGS LLC | 2008-07-03 | — | — | US | disclosed |
| CN-101193882-A | N-formyl hydroxylamine compounds as PDF inhibitors | NOVARTIS AG (CH) | 2008-06-04 | — | — | CN | disclosed |
| EP-1896452-A2 | N-FORMYL HYDROXYLAMINE COMPOUNDS | Novartis Pharma AG. (CH) | 2008-03-12 | — | — | EP | disclosed |
| WO-2007106670-A2 | N-FORMYL HYDROXYLAMINE COMPOUNDS | NOVARTIS AG (CH) | 2007-09-20 | — | — | WO | disclosed |
| WO-2006127576-A2 | N - FORMYL HYDROXYLAMINE COMPOUNDS AS PDF INHIBITORS | NOVARTIS AG (CH) | 2006-11-30 | — | — | WO | disclosed |
| US-20020094989-A1 | Pyrrolidine modulators of CCR5 chemokine receptor activity | HALE JEFFREY J (US) | 2002-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063278-A1 | N-Formyl Hydroxylamines compounds | PDF, MMP2, HNMT | SLC1A3 3131/4885SLC1A2 3161/4885SLC1A1 2715/4885 |
| US-20020094989-A1 | Pyrrolidine modulators of CCR5 chemokine receptor activity | CCR5, CCR1, CXCR1 | SLC1A3 2454/4885SLC1A2 2834/4885SLC1A1 1540/4885 |
| US-20090062537-A1 | N-Formyl Hydrozyamine Compounds | PDF, HNMT, MMP2 | SLC1A3 2155/4885SLC1A2 2491/4885SLC1A1 1882/4885 |
| US-20080161558-A1 | 1-[2-Cyclopentylmethyl-3-(formyl-hydroxy-amino)-propionyl]-pyrrolidine-2-carboxylic acid (5-fluoro-1-oxy-pyridin-2-yl)-amide; inhibitors of peptidyl deformylase (PDF), antimicrobials and antibiotics | PDF, MMP2, PEPD | SLC1A3 2822/4885SLC1A2 2929/4885SLC1A1 2462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.